AIO-YMO/TRK-0120 Phase II Studie zu Osimertinib und Strahlentherapie bei EGFR+, fortgeschrittenem nichtkleinzelligem Lungenkrebs (Aktiv)
ARROS-1 (NVL-520-01) Phase-1/2-Studie zu NVL-520 bei Patienten mit fortgeschrittenem NSCLC und anderen soliden Tumoren (Aktiv)
MAGELLAN Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location (Aktiv)
MK-3475-587 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)
Rezilient 2 An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations. (Aktiv)
SenPET Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)
Trident-1 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Aktiv)
ABP Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (Aktiv)
BI 1479-0008 (Phase III) Phase-3-Studie zu BI 1810631 bei Patienten mit fortgeschrittenem oder metastasiertem nicht-kleinzelligem Lungenkrebs mit HER2-Mutationen (Aktiv)
BO42777 A Phase I-III, Multicenter Study Evaluating The Efficacy And Safety Of Multiple Therapies In Cohorts Of Patients Selected According To Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (Aktiv)
COCOON A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib (Aktiv)
CRISP Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (Aktiv)
CodeBreaK 202 A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (Aktiv)
DESTINY-Lung04 Eine offene, randomisierte, multizentrische Phase-III-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Trastuzumab Deruxtecan (T-DXd) im Vergleich zu Chemotherapie plus Pembrolizumab für die Erstlinienbehandlung von fortgeschrittenem/metastasiertem nicht-squamösem nicht-kleinzelligem Lungenkrebs mit HER2 Exon 19 oder 20 Mutation (Aktiv)
DZ2022E0005 A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation (Aktiv)
ESPADURVA Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA) (Aktiv)
FINN (CA209-7MA) Eine deutsche, landesweite, prospektive, multizentrische Beobachtungsstudie an Patienten mit Erstlinientherapie mit Nivolumab plus Ipilimumab in Kombination mit zwei Chemotherapiezyklen bei metastasiertem nicht-kleinzelligem Lungenkrebs (Aktiv)
GSK-213824 A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer (Aktiv)
LCNEC-ALPINE A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)
LIBRETTO-432 (J2G-MC-JZJX) A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (Aktiv)
MO41552 Randomized, Open Label, Multicenter, Phase III Study Of Entrectinib Versus Crizotinib In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Harboring Ros1 Gene Rearrangements With And Without Central Nervous System Metastases (Aktiv)
NEOpredict (CA224-063) Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (Aktiv)
NEOpredict-EGFR Preoperative amivantamab or amivantamab and carboplatin/pemetrexed treatment in patients with resectable non-small-cell lung cancer harboring oncogenic EGFR mutations (Aktiv)
PACE-LUNG Phase II Studie zu zusätzlicher Chemotherapie bei EGFR-positivem nicht-kleinzelligem Lungenkrebs (Aktiv)
PACIFIC-8 Eine globale Studie zur Bewertung der Auswirkungen von Durvalumab + Domvanalimab nach gleichzeitiger Radiochemotherapie bei Teilnehmern mit inoperablem nicht-kleinzelligem Lungenkrebs im Stadium III (PACIFIC 8) (Aktiv)
PALOMA-2 A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in multiple regimens in patients with Advanced or Metastatic Solid Tumors including EGFR mutated NSCLC (PALOMA-2) (Aktiv)
PRONTOX Protonenbehandlung zur primären Radiochemotherapie bei fortgeschrittenen Nicht-kleinzelligen Bronchialkarzinomen (Aktiv)
Paccelio PACCELIO- FDG-PET based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (Aktiv)
RAZOR Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer (Aktiv)
Roche Horizon 1(BO42777) A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (Aktiv)
TRADE-hypo Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (Aktiv)
TRIDENT-3 Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naive ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (Aktiv)
TROPION-Lung08 A randomized open-label phase 3 trial of Dato-DXd plus Pembrolizumab vs Pembrolizumab alone in treatment naïve subjects with advanced or metastatic PD-L1 High (TPS>= 50%) NSCLC without actionable genomic alterations (Tropion-LUNG08) (Aktiv)
TroFuse-007 A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (Aktiv)
Tropion-Lung07 A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (Aktiv)
eVOLVE-Lung02 (D798AC00001) A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC). (Aktiv)
Zweitlinie oder später
AbbVieM18-868 Eine offene, randomisierte, kontrollierte, globale Phase-3-Studie mit Telisotuzumab Vendotin (ABBV-399) im Vergleich zu Docetaxel bei Patienten mit zuvor behandeltem c-Met-überexprimierendem EGFR-Wildtyp, lokal fortgeschrittenem/metastasiertem, nicht-squamösem nicht-kleinzelligem Lungenkrebs. (Aktiv)
Antelope Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma (Aktiv)
BI 1403-0011 - BRIGHTLINE-2 Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours (Aktiv)
BNT116-01 LuCa-MERIT-1 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (Aktiv)
Be6A LUNG-01(SGNB6A-002) A Randomized, Phase 3, Open-label Study to Evaluate SGN-B6A Compared With Docetaxel in Adult Subjects With Previously Treated Non-small Cell Lung Cancer (Aktiv)
BoB Module 1 A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)
CMGY825A12101 Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (Aktiv)
D533BC00001 A Phase III, Open-Label, Randomised, Multicentre Study Of Ceralasertib Plus Durvalumab Versus Docetaxel In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, And Whose Disease Has Progressed On Or After Prior Anti-PD-(L)1 Therapy And Platinum-Based Chemotherapy: LATIFY (Aktiv)
GSK ICOS A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants (Aktiv)
Krascendo 1 A Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Divarasib versus Sotorasib or Adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic non-small cell lung cancer. (Aktiv)
L-AP-IS Lunge L-AP-IS: Lung cancer, Ablative high Precision radiotherapy and the Immune System: Evaluation of the immune-modulatory effects of stereotactic body radiation therapy (SBRT) of pulmonary lesions (Aktiv)
MCLA-128-CL01/MERUS A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)
MK-2870-004 A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (Aktiv)
Novartis CFKA115A12101 A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers (Aktiv)
Pacific-9 A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) D9078C00001 (Aktiv)
RadImmun-NSCLC Evaluierung von systemischen Effekten der kombinierten palliativen Strahlen- und Immuntherapie bei nicht kleinzelligem Bronchialkarzinom nach unzureichendem Ansprechen auf Immun-Checkpoint-Inhibitoren (Aktiv)
SORATRAM Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)
VALO-001 Phase I Studie zu einer Erstlinientherapie bei Nicht-Kleinzelligem Lungenkarzinom, Schwarzem Hautkrebs oder Brustkrebs (Aktiv)